目的:先前的研究提示不同类型的他汀类药物可能对青光眼发病风险产生不同的影响。本研究旨在综合评价各种他汀类药物对青光眼发生风险的影响。
方法:PubMed,科克伦中部,Embase,和WebofScience从1994年2月到2024年2月进行了搜索。我们纳入了调查各种类型他汀类药物效果的研究,贝多类,ezetimibe,胆甾胺,烟酸,PCSK9抑制剂,omega-3脂肪酸,和任何降胆固醇药物对青光眼的发作或进展。修订后的Cochrane用于随机试验的偏倚风险工具(RoB2.0)和非随机干预研究中的偏倚风险(ROBINS-1)工具用于评估随机对照试验(RCT)和非随机对照试验的质量。分别。使用频繁网络元分析框架来评估比较有效性,应用了随机效应模型。
结果:这项网络荟萃分析包括12项研究,涵盖262,217名个体,包括他汀类药物等降胆固醇药物,贝多类,ezetimibe,胆甾胺,烟酸,和omega-3脂肪酸.我们的研究结果表明,与安慰剂相比,瑞舒伐他汀(风险比[RR],1.23;95%置信区间[CI],1.03to1.46),辛伐他汀(RR,1.21;95%CI,1.02至1.43),和普伐他汀(RR,1.20;95%CI,1.01~1.43)增加青光眼发病风险,具有统计学意义。
结论:瑞舒伐他汀,辛伐他汀,和普伐他汀均与青光眼发病风险显著增加相关.我们建议医生在为有青光眼风险的患者开具这些特定他汀类药物时要谨慎。
结论:已知先前的研究表明他汀类药物与发生青光眼的风险之间存在联系。然而,关于每种他汀类药物对青光眼发作的具体影响仍存在争议.该网络荟萃分析全面评估了各种他汀类药物对青光眼发病风险的影响。瑞舒伐他汀,辛伐他汀,和普伐他汀与青光眼发病风险显著增加相关.
OBJECTIVE: Previous studies implied that different types of statins may pose divergent impacts on the risk of glaucoma onset. This study aimed to comprehensively evaluate the effects of various statins on the risk of glaucoma occurrence.
METHODS: PubMed, Cochrane CENTRAL, Embase, and Web of Science were searched from February 1994 to February 2024. We included studies that investigated the effects of various types of statins, fibrates, ezetimibe, cholestyramine, niacin, PCSK9 inhibitors, omega-3 fatty acids, and any cholesterol-lowering medications on glaucoma onset or progression. The revised Cochrane risk-of-bias tool for randomized trials (RoB 2.0) and the Risk Of Bias In Non-randomized Studies-of Interventions (ROBINS-1) tool were used to assess the quality of randomized controlled trials (RCTs) and non-RCTs, respectively. The frequentist network meta-analysis framework was utilized to evaluate the comparative effectiveness, with the random effects model applied.
RESULTS: This network meta-analysis comprised 12 studies, encompassing 262,217 individuals and including cholesterol-lowering medications such as statins, fibrates, ezetimibe, cholestyramine, niacin, and omega-3 fatty acids. Our findings demonstrate that comparing to the placebo, rosuvastatin (risk ratio [RR], 1.23; 95% confidence interval [CI], 1.03 to 1.46), simvastatin (RR, 1.21; 95% CI, 1.02 to 1.43), and pravastatin (RR, 1.20; 95% CI, 1.01 to 1.43) increased the risk of glaucoma onset with statistical significance.
CONCLUSIONS: Rosuvastatin, simvastatin, and pravastatin were each associated with a significantly increased risk of glaucoma onset. We advise medical practitioners to exercise caution when prescribing these specific statins for patients who are at risk of developing glaucoma.
CONCLUSIONS: What is known Previous studies have suggested a link between statins and the risk of developing glaucoma. However, there is still ongoing debate regarding the specific effects of each type of statin on the onset of glaucoma. What is new This network meta-analysis comprehensively evaluated the effects of various statins on the risk of glaucoma onset. Rosuvastatin, simvastatin, and pravastatin were associated with a significantly increased risk of glaucoma onset.